Sharief M K, Thompson E J
Department of Clinical Neurochemistry, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
J Neurol Neurosurg Psychiatry. 1993 Feb;56(2):169-74. doi: 10.1136/jnnp.56.2.169.
Concentrations of interleukin-2 (IL-2) and soluble IL-2 receptor (sIL-2R) in serum and CSF samples were measured in 63 patients with multiple sclerosis (MS) to evaluate their usefulness as markers of disease activity. CSF concentrations of IL-2 and sIL-2R were significantly higher in MS relapse compared with MS patients in remission or with control subjects. These concentrations correlated with the clinical score by which disease severity was assessed, with the number of relapses per year, and with the total disease duration. Furthermore, there was evidence of intrathecal release of IL-2 and sIL-2R in clinically active MS. The results extend the notion that an activated cellular immune state parallels the evolution of the pathological process in MS and suggest that measurement of IL-2 and sIL-2R concentrations may provide an objective marker of disease activity in patients with MS.
检测了63例多发性硬化症（MS）患者血清和脑脊液样本中白细胞介素-2（IL-2）和可溶性IL-2受体（sIL-2R）的浓度，以评估它们作为疾病活动标志物的效用。与缓解期的MS患者或对照组相比，MS复发期患者脑脊液中IL-2和sIL-2R的浓度显著更高。这些浓度与评估疾病严重程度的临床评分、每年的复发次数以及疾病总病程相关。此外，在临床活动期的MS患者中存在IL-2和sIL-2R鞘内释放的证据。这些结果扩展了这样一种观念，即活化的细胞免疫状态与MS病理过程的演变平行，并表明检测IL-2和sIL-2R浓度可能为MS患者的疾病活动提供一个客观标志物。
